Category North America

Special Report: European Dialogue On Internet Governance: Regulating Cyberspace After Prism?

Lisbon, Portugal - The surveillance affair around the US Prism programme left its mark on the 2013 European Dialogue on Internet Governance (EuroDIG) in Lisbon last week. Legal experts at the sixth edition of the European version of the Internet Governance Forum pondered possible legal reactions, companies revealed as targets or (unwilling) partners of the programme tried to limit the damage, while Swedish ambassador Olaf Ehrenkrona admitted that state surveillance programs need to be reconsidered given the ease of mass surveillance in the era of a public internet space.

US Gives Boost To Materials Genome Initiative

The Obama administration and academic and industry partners today announced their commitment to support the Materials Genome Initiative (MGI), a public-private endeavor whose aim is to reduce the time required to develop novel materials that can “fuel advanced manufacturing and bolster the 21st century American economy.”

US Supreme Court Rules On Pharma Payments To Delay Generic Drugs On Market

The United States Supreme Court in a five to three decision today found that settlement agreements by branded pharmaceutical companies involving payments to generic companies to delay their cheaper drugs' entry into the market may not be immune from antitrust scrutiny but are not "presumptively" unlawful. The case was sent back to lower court.

US Supreme Court Restricts Gene Patents … A Little

Last Thursday, the United States Supreme Court overturned more than 30 years of precedents and ruled that isolated genes cannot be patented. They are products of nature and thus not patent-eligible subject matter, the court unanimously held in Assoc. for Molecular Pathology v. Myriad Genetics, Inc. This ruling puts the US at odds with most other nations, which allow genes to be patented. But because other major nations grant narrower gene patents, the net effect of Myriad will be to shift the US position on gene patents closer to that of other nations.